"HLA-A24 Antigen" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A specific HLA-A surface antigen subtype. Members of this subtype contain alpha chains that are encoded by the HLA-A*24 allele family.
| Descriptor ID |
D059871
|
| MeSH Number(s) |
D12.776.395.550.489.400.240 D12.776.543.550.439.400.240 D23.050.301.500.100.400.240 D23.050.301.500.450.370.240 D23.050.705.552.100.400.240 D23.050.705.552.450.370.600
|
| Concept/Terms |
HLA-A24 Antigen- HLA-A24 Antigen
- Antigen, HLA-A24
- HLA A24 Antigen
- HLA A24
- HLA-A24
|
Below are MeSH descriptors whose meaning is more general than "HLA-A24 Antigen".
Below are MeSH descriptors whose meaning is more specific than "HLA-A24 Antigen".
This graph shows the total number of publications written about "HLA-A24 Antigen" by people in this website by year, and whether "HLA-A24 Antigen" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 0 | 1 | 1 |
| 2004 | 0 | 2 | 2 |
| 2005 | 0 | 1 | 1 |
| 2007 | 1 | 0 | 1 |
| 2008 | 0 | 1 | 1 |
| 2009 | 0 | 1 | 1 |
| 2011 | 0 | 1 | 1 |
| 2012 | 1 | 1 | 2 |
| 2016 | 0 | 2 | 2 |
| 2017 | 1 | 2 | 3 |
| 2018 | 0 | 1 | 1 |
| 2019 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "HLA-A24 Antigen" by people in Profiles.
-
Effective desensitization for a strong donor-specific HLA antibody in a case of HLA-mismatched allogeneic hematopoietic cell transplantation. HLA. 2019 09; 94(3):307-311.
-
Immunotherapy with cancer peptides in combination with intravesical bacillus Calmette-Guerin for patients with non-muscle invasive bladder cancer. Cancer Immunol Immunother. 2018 Sep; 67(9):1371-1380.
-
Phase I clinical trial of cell division associated 1 (CDCA1) peptide vaccination for castration resistant prostate cancer. Cancer Sci. 2017 Jul; 108(7):1452-1457.
-
Multiple therapeutic peptide vaccines for patients with advanced gastric cancer. Int J Oncol. 2017 May; 50(5):1655-1662.
-
Predictive biomarkers for the efficacy of peptide vaccine treatment: based on the results of a phase II study on advanced pancreatic cancer. J Exp Clin Cancer Res. 2017 02 28; 36(1):36.
-
Phase II clinical trial of peptide cocktail therapy for patients with advanced pancreatic cancer: VENUS-PC study. Cancer Sci. 2017 Jan; 108(1):73-80.
-
Phase I clinical trial of a five-peptide cancer vaccine combined with cyclophosphamide in advanced solid tumors. Clin Immunol. 2016 05; 166-167:48-58.
-
Phase I/II study of S-1 plus cisplatin combined with peptide vaccines for human vascular endothelial growth factor receptor 1 and 2 in patients with advanced gastric cancer. Int J Oncol. 2012 Oct; 41(4):1297-304.
-
Identification of HLA-A24-restricted novel T Cell epitope peptides derived from P-cadherin and kinesin family member 20A. J Biomed Biotechnol. 2012; 2012:848042.
-
A novel tumor-associated antigen, cell division cycle 45-like can induce cytotoxic T-lymphocytes reactive to tumor cells. Cancer Sci. 2011 Apr; 102(4):697-705.